Therapeutic blockade of the PD-1/PD-L1 immune checkpoint pathways unleashes CD8+ T cell-mediated immune power against cancer and is a promising clinical anti-tumor therapeutic modality [5, 6]. This evidence concerns the gene CD8A and neoplasm.